New pharmacological approaches to the treatment of schizophrenia

Turk Psikiyatri Dergisi

Volumn 20, Issue 2, 2009, Pages 1-8

  Uzbay, I Tayfun ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Agmatine; Antipsychotic drugs; Dopaminergic system; Nitric oxide; Schizophrenia

Indexed keywords

EID: 68649117924     PISSN: 13002163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Anton RF, Kranzler H, Breder C et al. (2008) A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol, 28: 5-12.
2. Aricioglu-Kartal F, Uzbay IT (1997) Inhibitory effect of agmatine on naloxone-precipitated abstinence syndrome in morphine dependent rats. Life Sci, 61: 1775-81.
3. Batel P (2000) Addiction and schizophrenia. Eur Psychiatry, 15: 115-22.
4. Benes FM, Paskevich PA, Davidson J et al. (1985) The effects of haloperidol on synaptic patterns in the rat striatum. Brain Res, 329: 265-73.
5. Bernstein HG, Bogerts B, Keilhoff G (2005) The many faces of nitric oxide in schizophrenia. A review. Schizophr Res, 78: 69-86.
6. Bersani G, Iannitelli A, Maselli P et al. (1999) Low nerve growth factor plasma levels in schizophrenic patients: a preliminary study. Schizophr Res, 25: 201-3.
7. Bilder RM, Wu H, Chakos MH et al. (1994) Cerebral morphometry and clozapine treatment in schizophrenia. J Clin Psychiatry, 55: 53-6.
8. Black MD, Selk DE, Hitchcock JM et al. (1999) On the effect of neonatal nitric oxide synthase inhibition in rats: a potential neurodevelopmental model of schizophrenia. Neuropharmacology, 38: 1299-306.
9. Blum K, Braverman ER, Holder JM et al. (2000) Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J Psychoactive Drugs, 32 (Suppl. i-iv):1-112.
10. Bowirrat A, Oscar-Berman M (2005) Relationship between dopaminergic neurotransmission, alcoholism, and reward deficiency syndrome. Am J Med Genet, 132B: 29-37.
11. Buchanan RW, Jawitt DC, Merder SR et al. (2007) The cognitive and negative symptoms in schizophrenia trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry, 164: 1593-602.
12. Chakos MH, Shirakawa O, Lieberman J et al. (1998) Striatal enlargement in rats chronically treated with neuroleptic. Biol Psychiatry, 44: 675-84.
13. Comings DE, Blum K (2000) Reward deficiency syndrome: genetic aspects of behavioral disorders. Prog Brain Res, 126: 325-41.
14. Davidson M (2005) Normal behaviour, abnormal behaviour and mental ill ness are biologically on a continuum. ECNP Newsletter, 8: 2-3.
15. Dawirs RR, Hildebrandt K, Teuchert-Noodt G (1998) Adult treatment with haloperidol increases dentate granule cell proliferation in the gerbil hippocampus. J Neural Transm, 105: 317-27.
16. Deutch AY, Duman RS (1996) The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: Cellular localization and pharmacological characterization. Neuroscience, 70: 377-89.
17. Doraiswamy PM, Tupler LA, Krishnan KR (1995) Neuroleptic treatment and caudate plasticity. Lancet, 345: 734-5.
18. Durany N, Michel T, Zoehling R et al. (2001) Brain-derived neurotrophic factor and neurotrophin-3 in schizophrenic psychoses. Schizophr Res, 52: 79-86.
19. Frost DO, Tamminga CA, Medoff DR et al. (2004) Neuroplasticity and schizophrenia. Biol Psychiatry, 56: 540-3.
20. Grillo RW, Ottoni GL, Leke R et al. (2007) Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J Psychiat Res, 41: 31-5.
21. Gur RE, Maany V, Mozley PD et al. (1998) Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am J Psychiatry, 155: 1711-7.
22. Gyertyán I, Sághy K (2007) The selective dopamine D3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats. Eur J Pharmacol, 572: 171-4.
23. Harrison PJ (2008) Metabotropic glutamate receptor agonists for schizophrenia. Br J Psychiatry, 192: 86-7.
24. Imre G (2007) The preclinical properties of a novel group II metabotropic glutamate receptor agonist LY379268. CNS Drug Rev, 13: 444-64.
25. Javitt DC (2002) Glycine modulators in schizophrenia. Curr Opin Investig Drugs, 3: 1067-72.
26. Javitt JC (2008) Glycine transport inhibitors and the treatment of schizophrenia. Biol Psychiatry, 63: 6-8.
27. Joyce JN, Millan MJ (2005) Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov Today, 10: 917-25.
28. Kaputlu I, Uzbay IT (1997) L-NAME inhibits pentylenetetrazole and strychinine-induced seizures in mice. Brain Res, 753: 98-101.
29. Karson CN, Griffin WS, Mrak RE et al. (1996) Nitric oxide synthase (NOS) in schizophrenia: Increases in cerebellar vermis. Mol Chem Neuropathol, 27: 275-84.
30. Kerns JM, Sierens DK, Kao LC et al. (1992) Synaptic plasticity in the rat striatum following chronic haloperidol treatment. Clin Neuropharmacol, 15: 488-500.
31. Klamer D, Engel JA, Svensson L (2001) The nitric oxide synthase inhibitor L-NAME, block phencyclidine-induced disruption of prepulse inhibition in mice. Psychopharmacology, 156: 182-6.
32. Konradi C, Heckers S (2001) Antipsychotic drugs and neuroplasticity: Insights into the treatment and neurobiology of schizophrenia. Biol Psychiatry, 50: 729-42.
33. Kranzler HR, Covault J, Pierucci-Lagha A et al. (2008) Effects of aripiprazole on subjective and physiological responses to alcohol. Alcohol Clin Exp Res, 32: 573-9.
34. Lane HY, Chang YC, Liu YC et al. (2005) Sarcosine or D-serine addon-treatment for acute exacerbation of schizophrenia: A randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry, 62: 1196-204.
35. Leveque JC, Macias W, Rajadhyaksha A et al. (2000) Intracellular modulation of NMDA receptor function by antipsychotic drugs. J Neurosci, 20: 4011-20.
36. Li G, Regunathan S, Barrow CJ et al. (1994) Agmatine: an endogenous clonidine-displacing substance in the brain. Science, 263: 966-9.
37. Lindsley CW, Shipe WD, Wolkenberg SE et al. (2006) Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Curr Top Med Chem, 6: 771-85.
38. Lortie MJ, Novotny WF, Peterson OW et al. (1996) Agmatine, a bioactive metabolite of arginine. J Clin Invest, 97: 413-20.
39. Malberg JE, Eisch AJ, Nestler EJ (2000) Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci, 20: 9104-110.
40. Martin LF, Kem WR, Freedman R (2004) Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology, 174: 54-64.
41. Martin LF, Freedman R (2007) Schizophrenia and the alpha7 Nicotinic Acetylcholine Receptor. Int Rev Neurobiol, 78: 225-46.
42. Micheli F, Heidbreder C (2006) Selective dopamine D3 receptor antagonists: a review 2001-2005. Recent Patents CNS Drug Discov, 1: 271-88.
43. Moncada S, Higgs A (1993) The L-arginine-nitric oxide pathway. N Engl J Med, 329: 2002-12.
44. Moore PK, Wallace P, Gaffen Z et al. (1993) 7-nitro indazole, an inhibitor of nitric oxide synthase exhibits anti-nociceptive activity in the mouse without increasing blood pressure. Br J Pharmacol, 108: 296-7.
45. Nguyen TV, Kosofsky BE, Birnbaum R et al. (1992) Differential expression of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc Natl Acad Sci USA, 89: 4270-4.
46. Olincy A, Stevens KE (2007) Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men. Biochem Pharmacol, 74: 1192-201.
47. Parikh V, Khan MM, Mahadik SP (2004a) Olanzapine counteracts reducion of brain-derived neurotrophic factor and TrkB receptors in rat hippocampus produced by haloperidol. Neurosci Lett, 356: 135-9.
48. Parikh V, Terry AV, Khan MM et al. (2004b) Modulation of nerve growth factor and choline acetyltransferase expression in rat hippocampus after chronic exposure to haloperidol, risperidone, and olanzapine. Psychopharmacology, 172: 365-74.
49. Park SW, Lee SK, Kim JM et al. (2006) Effects of quetiapine on the brain-derived neurotrophic factor expression in the hippocampus and neocortex of rats. Neurosci Lett, 402: 25-29.
50. Pietraszek M, Nagel J, Gravius A et al. (2007) The role of group I metabotropic glutamate receptors in schizophrenia. Amino Acids, 32: 173-8.
51. Piletz JE, Chikkala DN, Ernsberger P (1995) Comparison of the properties of agmatine and endogenous clonidine-displacing substance at imidazoline and alpha 2-adrenergic receptors. J Pharmacol Exp Ther, 272: 581-7.
52. Ramchand CN, Das I, Gliddon A et al. (1994) Role of polyamines in the membrane pathology of schizophrenia. A study using fibroblasts from schizophrenic patients and normal controls. Schizophr Res, 13: 249-53.
53. Regunathan S, Reis DJ (1996) Imidazoline receptors and their endogenous ligands. Ann Rev Pharmacol Toxicol, 36: 511-44.
54. Robertson GS, Fibiger HC (1996) Effects of olanzapine on regional c-fos expression in rat forebrain. Neuropsychopharmacology, 14: 105-110.
55. Schatzberg AF, Cole JO, DeBattista C (2003) Manuel of Clinical Pharmacology. Fourth Edition, Washington DC, American Psychiatric Publishing, Inc.
56. Shahid M, Walker GB, Zorn SH et al. (2008) Asenapine: a novel psychopharmacologicagent with a unique human receptor signature. J Psychopharmacol, (in press).
57. Shihabuddin L, Buchsbaum MS, Hazlett EA et al. (1998) Dorsal striatal size, shape, and metabolic rate in never-medicated and previously medicated schizophrenics performing a verbal learning task. Arch Gen Psychiatry, 55: 235-43.
58. Shoval G, Weizman A (2005) The possible role of neurotrophins in the pathogenesis and therapy of schizophrenia. Eur Neuropharmacol, 15: 319-29.
59. Snyder SH, Bredt DS (1992) Biological roles of nitric oxide. Sci Am, May: 68-77.
60. Stefan M, Travis M, Murray RM (2002) An Atlas of Schizophrenia. London, The Parthenon Publishing Group.
61. Swayze VW, Andreasen NC, Alliger RJ et al. (1992) Subcortical and temporal structures in affective disorder and schizophrenia: a magnetic resonance imaging study. Biol Psychiatry, 31: 221-40.
62. Swerdlow NR, Martinez ZA, Hanlon FM et al. (2000) Toward understanding the biology of a complex phenotype: Rat strain and substrain differences in the sensorimotor gating-disruptive effects of dopamine agonists. J Neurosci, 20: 4325-336.
63. Taneli F, Pi{dotless}ri{dotless}ldar S, Akdeniz F et al. (2004) Serum nitric oxide metabolite levels and the effect of antipsychotic therapy in schizophrenia. Arch Med Res, 35: 401-5.
64. Toyoka K, Asama K, Watanabe Y et al. (2002) Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients. Psychiatry Res, 110: 249-57.
65. Tsai G, Coyle JT (2002) Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol, 42: 165-79.
66. Turner BJ, Rembach A, Spark R et al. (2003) Opposing effects of low and high-dose clozapine on survival of transgenic amyotrophic lateral sclerosis in mice. J Neurosci Res, 74: 605-13.
67. Unsalan N, Saglam E, Kayir H et al. (2008) Effects of olanzapine on ethanol withdrawal syndrome in rats. Eur J Pharmacol, 579: 208-14.
68. Uranova NA, Orlovskaya DD, Apel K et al. (1991) Morphometric study of synaptic patterns in the rat caudate nucleus and hippocampus under haloperidol treatment. Synapse, 7: 253-9.
69. Uzbay IT, Yeşilyurt Ö, Çelik T et al. (2000) Effects of agmatine on ethanol withdrawal syndrome in rats. Behav Brain Res, 107: 153-9.
70. Uzbay İT, Oglesby MW (2001) Nitric oxide and substance dependence. Neurosci Biobehav Rev 25: 43-52.
71. Uzbay IT (2007) Nöropsikofarmakoloji: Rasyonel ilaç kullanim. İstanbul, Yorum Yayi{dotless}nci{dotless}li{dotless}k - İstanbul Ti{dotless}p Kitabevi, s. 81-99.
72. Uzbay IT, Kayir H, Goktalay G et al. (2008) Şizofreni tedavisi için yeni bir farmasötik şekil. Resmi Patent Bülteni, 2008-02: 438.
73. Uzbay IT, Kayir H, Göktalay G et al. (2008b) Agmatine induces schizophrenia like-symptom in Wistar rats. European Neuropsychopharmacol, 18 (Suppl. 4): S399.
74. Uzbay IT, Kayir H, Göktalay G et al. (2009) Agmatine disrupts prepulse inhibition of acoustic startle reflex in rats. J Psychopharmacol (in press).
75. Wan V, Ennulat DJ, Cohen BM (1995) Acute administration of typical and atypical antipsychotic drugs induces distinctive patterns of Fos expression in the rat forebrain. Brain Res, 688: 95-104.
76. Weickert CS, Hyde TM, Lipska BK et al. (2003) Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Mol Psychiatry, 8: 592-610.
77. Wolley DW, Shaw E (1954) A biological and pharmacological suggestion about certain mental disorders. Proc Natl Acad Sci USA, 40: 228-31.
78. Woodruff-Pak DS, Gould TJ (2002) Neuronal nicotinic acetylcholine receptors: involvement in Alzheimer's disease and schizophrenia. Behav Cogn Neurosci Rev, 1: 5-20.
79. Xiberas X, Martinot JL, Mallet L et al. (2001) In vivo ekstrastriatal and striatal D2 dopamine receptor blockade by amisulpiride in schizophrenia. J Clin Psychopharmacol, 21: 207-214.
80. Yamada K, Noda Y, Nakayama S et al. (1995) Role of nitric oxide in learning and memory and in monoamine metabolism in the rat brain. Br J Pharmacol, 115: 852-8.
81. Yani{dotless}k M, Vural H, Kocyigit A et al. (2003) Is the argininenitric oxide pathway involved in the pathogenesis of schizophrenia? Neuropsychobiology, 47: 61-65.
82. Yao JK, Leonard S, Reddy RD (2004) Increased nitric oxide radicals in postmortem brain rom patients with schizophrenia. Schizophr Bull, 30: 923-934.
83. Yi{dotless}ldi{dotless}z F, Ulak G, Erden BF et al. (2000) Anxiolytic-like effects of 7-nitroindazole in the rat plus-maze test. Pharmacol Biochem Behav, 65: 199-202.